Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The open-house agreement may be terminated if a standard discount contract is concluded for Sorafenib, potentially redu...
No estimated value or guaranteed volume is disclosed. The discount may not generate sufficient revenue without committe...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive drug discount agreements for Sorafenib (ATC L01EX02) with AOK Bayern.
- Agreements are identical and non-negotiable for all participants.
Show full summary
This is an open-house model (not a competitive tender) by AOK Bayern for non-exclusive drug discount agreements on the active ingredient Sorafenib (ATC L01EX02) under §130a Abs. 8 SGB V. Any eligible pharmaceutical company can join by submitting a signed contract and a self-declaration of reliability. Contracts run from 01.11.2024 to 31.10.2026, with possible earlier termination if a standard discount contract comes into effect. No estimated value is provided.
Risks
The open-house agreement may be terminated if a standard discount contract is concluded for Sorafenib, potentially redu...
No estimated value or guaranteed volume is disclosed. The discount may not generate sufficient revenue without committe...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- If signing authority is not evident from the commercial register, a power of attorney must be provided.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- Submission of a signed contract (in duplicate if in writing) and a signed self-declaration of reliability.
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Sorafenib, ATC L01EX02
Non-exclusive discount agreements for Sorafenib. Open to all interested pharmaceutical companies meeting the eligibility criteria. No selection or award criteria – all eligible participants are accepted.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 557828-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The open-house agreement may be terminated if a standard discount contract is concluded for Sorafenib, potentially redu...
No estimated value or guaranteed volume is disclosed. The discount may not generate sufficient revenue without committe...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications